Safety Assessment of Propranolol for Infantile Hemangiomas Highlights Cardiovascular Risks
Real-world assessment of propranolol treatment for infantile hemangiomas indicates potential cardiovascular side effects.
Phase III
Dermatology / Infantile Hemangiomas
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The safety assessment of propranolol for treating infantile hemangiomas reveals potential cardiovascular risks, which could alter prescribing practices among dermatologists. This necessitates a review of treatment guidelines and patient education to ensure safety in clinical practice.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for further studies on the safety of propranolol and any changes in treatment recommendations for infantile hemangiomas.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.